The Melanoma Nursing Initiative – Home › Forums › Immunotherapy › Dosing and administration › Infusion times › Reply To: Infusion times
March 9, 2018 at 6:04 pm #4737
Expert NurseMollie Reed
I think it will certainly decrease volumes in the clinic. I also think that it could impact which treatment providers choose – pembrolizumab vs. nivolumab. I know that certain providers chose pembro based on the fact that dosing is less frequent while others who like to see patients more frequently chose nivo. I do know that my nivo patients will be thrilled with the once monthly dosing!